Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Bladder Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Florida, Gainesville, Florida, United States
Contact: Study coordinator (Karine Charles) · kmcharles@ufl.edu · 352-294-5018

Study leads

Paul Crispen, MD
Principal Investigator
University of Florida

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

Urinary Bladder Cancer

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Non-muscle-invasive Bladder Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Mesa, United States · Tucson, United States

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Non Muscle Invasive Bladder Cancer · High-grade Ta/ T1 Papillary Disease Bladder Cancer

Abroad (travel likely)RecruitingPHASE2

Beijing, China · Chongqing, China

RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients

Bladder Cancer · Muscle-Invasive Bladder Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Guangzhou, China